Naurex is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat depression as well as orphan and other challenging diseases of the central nervous system (CNS) treated in specialty settings. All of our programs, including two rapid-acting antidepressants currently in clinical development, stem from our proprietary platform for discovering novel compounds that act at the NMDA receptor (NMDAR) through a new mechanism of action to modulate neuronal plasticity.

The Naurex Breakthrough: Novel NMDA Receptor Modulators

Naurex researchers have generated novel chemical drug classes and a platform for discovering molecules that are partial agonists of the NMDA receptor. These partial agonists modulate the NMDA receptor in a different way than existing agents, exhibiting the remarkable efficacy potential of drugs such as ketamine, but without their limiting side effects. Naurex’s drug development programs include compounds with high potential for the treatment of mood and anxiety disorders, cognitive disorders, neurodegenerative diseases, developmental disorders, neuropathic pain, and addiction.